Clinical Trial Update: Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of OSI-211 (liposomal lurtotecan) for recurrent small cell lung cancer; the study has completed and reports on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• OSI-211 (Liposomal Lurtotecan) (liposomal lurtotecan)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: SCLC, Carcinoma, Small Cell | Phase 2 | Status: COMPLETED